Possibility of Predicting Pelvic Inclination Following Total Hip Arthroplasty Based on the Preoperative State: Sacral Slope and Pelvic Incidence Minus Lumbar Lordosis as Predictive Factors

Following total hip arthroplasty (THA), some patients exhibit anterior or posterior pelvic tilt (PT). This case– control study investigated whether changes to PT following THA can be preoperatively predicted. Methods: 135 patients with hip osteoarthritis who underwent THA were assessed. The parameters measured preoperatively and one year postoperatively were lumbar lordosis (LL) based on plain X-ray and pelvic incidence (PI), PT, and sacral slope (SS), all of which were measured as pelvic morphological angles. Patients were classified into groups (A–E) based on the degree of post-THA PT, and their preoperative conditions were compared. PI minus LL was used to evaluate spinal alignment and pelvic balance. Results: Overall, 33%, 30%, 21%, 13%, and 3% of the hips of patients in Groups A, B, C, D, and E were postoperatively assessed. In Groups A–E, the SS values were 34.6°±8.9°, 37.6°±8.4°, 37.9°±8.9°, 42.6°±9.5°, and 60.0°±11.1°, whereas the PI minus LL values were 2.9°±15.0°, 1.2°±13.6°, 3.6°±17.7°, 12.7°±13.1°, and −1.3°±11.7°, respectively. Conclusions: Following THA, 70% of patients experienced posterior PT. Pre-THA SS ≥45° or PI minus LL ≥15° signified marked postoperative posterior tilt and could predict postoperative PT following THA. These findings are useful for implant placement, as they can predict pelvic inclination

Comparison between Cases of Total Hip Arthroplasty Followed by Colonna Capsular Arthroplasty and Lorenz Cast Reduction in Patients with Developmental Dysplasia of the Hip

Most patients with developmental dysplasia of the hip (DDH) now receive closed-reduction treatment within 6 months after birth. The long-term outcomes of patients with late-detection DDH have remained unclear. We reviewed the clinical records of 18 patients who underwent Colonna capsular arthroplasty (n=8) or closed reduction (n=10) for developmental dysplasia of the hip as infants or young children and underwent total hip arthroplasty approximately in midlife. Both the Colonna capsular arthroplasty and closed reduction groups achieved good clinical results after total hip arthroplasty. However, the operating time was longer and the improvements of hip range of motion and clinical score were significantly worse in the Colonna capsular arthroplasty group than in the closed reduction group

Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone–related protein in secondary parathyroid hyperplasia

Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia.BackgroundParathyroid hormone–related protein (PTHrP) is now suspected to act as an autocrine or paracrine regulator of cell growth or differentiation, although it was originally reported as a hypercalcemic substance in malignancies. This study was performed to assess the relationship between PTHrP expression and cell proliferation in human parathyroid glands.MethodsThe localization of PTH and PTHrP was studied in 42 samples of hyperplastic parathyroid from 14 long-term hemodialysis cases with immunohistochemistry and in situ hybridization. Results were compared with proliferative activity (proliferating cell nuclear antigen index: counts of proliferating cell nuclear antigen-positive cells/100 cells). The localization of the PTH/PTHrP receptor was also examined. Ten normal glands were studied as controls.ResultsIn hyperplasia, cells positive for PTH, PTHrP, or both were observed immunohistochemically. The areas expressing PTHrP mRNA completely coincided with those positive for PTHrP immunohistochemically. Oxyphilic or transitional oxyphilic cells were consistently positive for PTHrP. PTH/PTHrP receptors were located in the cytoplasmic membrane in most parathyroid cells. Proliferating cell nuclear antigen-positive cells were rare in normal glands with an index of 0.22 ± 0.09 (mean ± sem). They were significantly increased in hyperplastic cases but less for PTHrP-positive than for -negative cells (1.25 ± 0.16 as compared with 7.80 ± 0.52; P < 0.0001).ConclusionThe observed low level of proliferation of PTHrP-positive cells suggests a functional role for PTHrP as a possible growth suppressor in the human parathyroid

A study on the assessment of painted concrete surface with hyperspectral remote sensing

特集 都市基盤の安全とICUSの活

Utility of a simplified ultrasonography scoring system among patients with rheumatoid arthritis: A multicenter cohort study

ABSTRACT: We aimed to evaluate the utility of a simplified ultrasonography (US) scoring system, which is desired in daily clinical practice, among patients with rheumatoid arthritis (RA) receiving biological/targeted synthetic disease-modifying antirheumatic drugs (DMARDs).A total of 289 Japanese patients with RA who were started on tumor necrosis factor inhibitors, abatacept, tocilizumab, or Janus kinase inhibitors between June 2013 and April 2019 at one of the 15 participating rheumatology centers were reviewed. We performed US assessment of articular synovia over 22 joints among bilateral wrist and finger joints, and the 22-joint (22j)-GS and 22-joint (22j)-PD scores were evaluated as an indicator of US activity using the sum of the GS and PD scores, respectively.The top 6 most affected joints included the bilateral wrist and second/third metacarpophalangeal joints. Therefore, 6-joint (6j)-GS and -PD scores were defined as the sum of the GS and PD scores from the 6 synovial sites over the aforementioned 6 joints, respectively. Although the 22j- or 6j-US scores were significantly correlated with DAS28-ESR or -CRP scores, the correlations were weak. Conversely, 6j-US scores were significantly and strongly correlated with 22j-US scores not only at baseline but also after therapy initiation.Using a multicenter cohort data, our results indicated that a simplified US scoring system could be adequately tolerated during any disease course among patients with RA receiving biological/targeted synthetic DMARDs